Received Date: January 06, 2016; Accepted Date: January 27, 2015; Published Date: February 03, 2016
Citation: Singh GK, Kaur J, Sharma D, Singh G, Singh P (2016) Isolated Clavicular Metastasis in a Patient with Endometrial Adenocarcinoma. Cervical Cancer 1:107.doi:10.4172/2475-3173.1000107
Copyright: © 2016 Singh GK, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Visit for more related articles at Cervical Cancer: Open Access
Endometrial adenocarcinoma metastasizing to bones is rare, and isolated metastasis to clavicle is even more uncommon. We report a case of a 60-year-old woman diagnosed with endometrial adenocarcinoma found to have isolated metastasis to the clavicle during adjuvant radiotherapy. Following radiation therapy to the clavicle, patient was started on injection zoledronic acid. She was then planned for chemotherapy comprising of Paclitaxel and Carboplatin for six cycles. Due to lack of compliance, 5months after the initial diagnosis, she developed severe dyspnea due to disease progression and expired. We hereby discuss the treatment options as well as review the literature of prior published reports on endometrial adenocarcinoma with bone metastasis.
Endometrial cancer; Clavicle metastases; Palliative radiotherapy; FIGO staging
Endometrial carcinoma is the sixth most common cancer among females worldwide following breast, colorectal, lung and cervical cancer . It is fourth most common in developed countries and seventh in ranking in developing countries in the females. About 90% of the uterine carcinomas are adenocarcinoma . Endometrial carcinoma usually extends by local invasion or shows lymphatic spread. Hematogenous dissemination is relatively infrequent. The common sites for distant metastases are lung, liver and brain. Metastasis to bone occurs in less than 15% of the patients with advanced disease and is generally restricted to pelvis and the vertebrae . We report herein a very rare case of endometrial adenocarcinoma (grade 3) with isolated metastasis to clavicle.
A 60 years old post menopausal female presented to the gynaecology OPD of another hospital with complains of vaginal bleeding and pelvic pain for 6 months. Endometrial biopsy revealed high grade endometrial adenocarcinoma. She underwent surgical staging with radical hysterectomy and bilateral salpingo-oopherectomy for the same 1 year back. Findings were consistent with FIGO stage IIIA grade 3 endometrial adenocarcinoma. She was referred to the outpatient department of our institute for postoperative radiotherapy. Patient was discussed in multidisciplinary clinic and was planned for adjuvant radiotherapy to whole pelvis to a dose of 50 Gy in 25 fractions by 4 field technique followed by Intra Vaginal Brachytherapy after proper consent. During the treatment (after receiving 14 Gy in 7 fractions of pelvic radiotherapy), she started complaining of pain and swelling in the left clavicular region. On local examination, the swelling was about 3×3 cm in size, hard, fixed to underlying structures; tender with normal overlying skin. The swelling was progressively increasing in size. The general physical examination was unremarkable.
Chest X-ray PA view revealed a lytic lesion in medial one third of left clavicle (Figure 1). Fine Needle Aspiration Cytology (FNAC) from the swelling revealed metastatic adenocarcinoma (Figure 2). On this basis, a complete metastatic workup was done, which showed no evidence of disease elsewhere. The final diagnosis was stage IV B endometrial adenocarcinoma with isolated metastasis to clavicle. The ongoing adjuvant radiotherapy was stopped and the patient was administered palliative radiotherapy of 20 Gy in 5 fractions to clavicle. Zoledronic acid was also administered later on. She was subsequently planned for systemic chemotherapy with Paclitaxel and carboplatin but she defaulted and reported 3 months later with severe breathing difficulty and progression in size of metastatic swelling about 10×10 cm in size (Figure 3). In spite of the best supportive care, patient expired after 5 months of initial diagnosis because of the disease progression.
A. Low power view -10×, showing loose cluster of tumor cells along with ill formed glands.Cells show pleomorphism with a high N:C ratio. B. High power view - 40×, showing round to ovoid tumor cells. The individual cells show pleomorphism, are large, with high N:C ratio and prominent nucleoli.
Figure 2: FNAC smear.
Endometrial carcinoma is the most common gynaecological cancer accounting for 6% of all new cases of cancer in developed countries (e.g. USA) . In India, the incidence is about 2.3% . The tumor is confined to the uterus itself in 75% of the cases . The incidence of bone metastasis from recurrent endometrial carcinoma is reported to be less than 15% . In an autopsy study by Abdul-Karim et.al., the incidence of bone metastasis was found to be 25-27% , which is highest among the reported literatures and the vertebrae were the most common site, only 6/67 cases had known bone metastases while they were alive and all had high grade carcinomas. Among the reported cases, the most common locations of bone metastasis in patients with a high surgical stage and grade are appendicular skeleton.
Several case reports show unusual sites of bony metastases from endometrial carcinoma, such as the calcaneum, humerus, mandible, talus, metatarsalsand skull [6-10]. The survival after bone metastasis was poor in cases of poorly differentiated (grade 3) adenocarcinoma treated with only local palliative radiotherapy to the bone [9,11,12], which is similar in our case.
Ali et al.  reported a case with metastatic high grade endometrial adenocarcinoma with bone metastasis, who survived for more than 16 months on multimodality treatment i.e. surgery of bone metastasis, hormone therapy for primary disease and local radiotherapy for metastasis. Dosoretz et al.  reported a case of poorly differentiated endometrial adenocarcinoma with isolated mandibular metastasis. After total abdominal hysterectomy and bilateral salpingooophorectomy; she was given radiation therapy to the mandible, and chemotherapy consisting of Paclitaxel and Carboplatin for six cycles. She had a complete response and survived for more than 14 months.
To the best of our knowledge, there are only two reported cases of endometrial adenocarcinoma metastasis to clavicle. First case was along with multiple lung metastases and second case with humerus [13,14], with our patient presented with isolated clavicular metastasis.
Our report presented has three main peculiar features:
1. Endometrial carcinoma presenting with bony metastasis, which is a rare entity.
2. An extremely rare site of metastatic tumor, located in the clavicle.
3. The lesion as a single bone metastasis, which is uncommon in such high grade cases.
According to review of literature, the most common treatment for metastasis to the bone is surgical removal of the lesion (if possible), radiation therapy to metastatic site and chemotherapy for a good clinical outcome . Our patient received local radiotherapy to the clavicle, along with zoledronic acid. Bisphosphonate was added as it has been shown to have a modest improvement in skeletal-related event-free survival according to case report by Shigemitsu et al. . Though planned for systemic chemotherapy, the patient did not comply, deteriorated rapidly and expired after about 3 months of initial diagnosis of bone metastasis.
Rare, metastatic endometrial adenocarcinoma should be considered as a differential diagnosis inpatients presenting with abnormal bony swelling and tenderness. Early diagnosis and treatment of such cases is essential as aggressive treatment with multimodality approach leads to prolonged survival [7,10]. For this, a high index of suspicion in these cases is required. Bone scans or conventional X-rays can be used. Palliation of symptoms should be done if combined modality is not possible.
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals